Continuing tyrosine kinase inhibitor (TKI)-mediated targeting of the BCR-ABL1 oncoprotein is the standard therapy for chronic myeloid leukemia (CML) and allows for a sustained disease control in the majority of patients. While therapy cessation for patients appeared as a safe option for about half of those patients with optimal response. no systematic assessment of long-term TKI dose ... https://www.roneverhart.com/S-mores-Snack-Mix-2LB-Bag/